This is consistent with previous reports that mutant MUC4 was correlated with higher TMB and potentially associated with prognosis in pancancer (Yang Y. et al., 2020), while XIRP2 mutation was potentially associated with metastasis in breast cancer (Paul et al., 2020). This evidence concerns the gene MUC4 and breast carcinoma.